A
Alcista
Alcista · 25%PFE
$32.01
Precio del escenario
$29.790
-0.238 (-0.80%)Al cierre
Loading chart…
- Máximo
- 30.305
- Apertura
- 30.000
- Precio medio ponderado por volumen
- 29.94
- Volumen
- 25.66M
- Capitalización
- 157.53B
- Mínimo
- 29.715
- Importe
- 768.07M
- EV/EBITDA, TTM
- 10.12
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
Análisis de IA of Pfizer Inc (PFE)
MantenerPfizer Inc is currently a hold. The stock is priced at $30.03, with a forward P/E ratio of 9.67, suggesting it may be undervalued relative to its earnings potential. However, the recent news indicates concerns about its dividend sustainability due to a payout ratio exceeding 100%.
Recomendaciones de analistas (22)
-4.13% Potencial de caída
Comprar
12 Comprar
9 Mantener
1 Vender
Actual: 29.79
Mínimo
24.00
Promedio
28.56
Máximo
35.00
JPMorgan
Neutral
$30
2026-10-09
JPMorgan
2026-10-09
Precio objetivo
$30
Neutral
BofA
Neutral
$29
2026-10-09
BofA
2026-10-09
Precio objetivo
$29
Neutral
Cantor Fitzgerald
Neutral
$28
2026-10-08
Cantor Fitzgerald
2026-10-08
Precio objetivo
$28
Neutral
Scotiabank
Superar al mercado
$33
2026-10-07
Scotiabank
2026-10-07
Precio objetivo
$33
Superar al mercado
Scotiabank
Superar al mercado
$33
2026-10-06
Scotiabank
2026-10-06
Precio objetivo
$33
Superar al mercado
Métricas de valoración
El PER previsto actual de Pfizer Inc (PFE) es 9.67, frente a su media de 5 años de 12.15.
Escenarios de precio de Alphio AI para PFE
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con PFE en cartera
Cronología de eventos
Noticias
8.510-26NewsfilterFDA Approves TALZENNA and XTANDI for Prostate Cancer Treatment
- 9.010-24Newsfilter
Pfizer's Investigational Vaccine Shows Strong Immune Responses in Infants
9.510-24CNBCBiotech Sector Recovery: Moderna Leads the Charge
9.510-24FoolPfizer's Dividend Outlook Amid Patent Challenges
- 8.010-23Fool
Dividend Comparison: Pfizer vs. Bristol Myers Squibb
Preguntas frecuentes sobre PFE, respondidas por Alphio AI
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Pfizer Inc is currently a hold. The stock is priced at $30.03, with a forward P/E ratio of 9.67, suggesting it may be undervalued relative to its earnings potential. However, the recent news indicates concerns about its dividend sustainability due to a payout ratio exceeding 100%.
22 analysts cover PFE: 12 rate it Buy, 9 Hold and 1 Sell. The average price target is 28.56.
Comunidad
Más ↗
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.